De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Stoke Therapeutics Beheer
Beheer criteriumcontroles 4/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Ed Kaye
Algemeen directeur
US$3.5m
Totale compensatie
| Percentage CEO-salaris | 17.7% |
| Dienstverband CEO | 7yrs |
| Eigendom CEO | 0.05% |
| Management gemiddelde ambtstermijn | 3.8yrs |
| Gemiddelde ambtstermijn bestuur | 6.1yrs |
Recente managementupdates
Recent updates
Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome
Sep 07We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Jul 22
Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome
Jun 14It Looks Like Stoke Therapeutics, Inc.'s (NASDAQ:STOK) CEO May Expect Their Salary To Be Put Under The Microscope
May 30Stoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The Watchlist
Apr 04Here's Why We're Watching Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Situation
Mar 21We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Dec 07Party Time: Brokers Just Made Major Increases To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Earnings Forecasts
May 09Analysts Are Upgrading Stoke Therapeutics, Inc. (NASDAQ:STOK) After Its Latest Results
May 06Stoke Therapeutics (NASDAQ:STOK) Is In A Strong Position To Grow Its Business
May 02We're Interested To See How Stoke Therapeutics (NASDAQ:STOK) Uses Its Cash Hoard To Grow
Dec 13Companies Like Stoke Therapeutics (NASDAQ:STOK) Can Afford To Invest In Growth
Aug 14Stoke Therapeutics GAAP EPS of -$0.63 beats by $0.05, revenue of $3.2M beats by $0.18M
Aug 08We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Apr 29Stoke Therapeutics (NASDAQ:STOK) Is In A Good Position To Deliver On Growth Plans
Jan 13We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Sep 30We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely
Jun 16Stoke Therapeutics EPS misses by $0.02
May 10We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely
Mar 03Stoke Therapeutics: A Preclinical Biopharma With A Multibillion Dollar Market Cap
Dec 14Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$104m |
| Mar 31 2024 | n/a | n/a | -US$109m |
| Dec 31 2023 | US$4m | US$626k | -US$105m |
| Sep 30 2023 | n/a | n/a | -US$103m |
| Jun 30 2023 | n/a | n/a | -US$105m |
| Mar 31 2023 | n/a | n/a | -US$99m |
| Dec 31 2022 | US$6m | US$596k | -US$101m |
| Sep 30 2022 | n/a | n/a | -US$100m |
| Jun 30 2022 | n/a | n/a | -US$96m |
| Mar 31 2022 | n/a | n/a | -US$94m |
| Dec 31 2021 | US$9m | US$568k | -US$86m |
| Sep 30 2021 | n/a | n/a | -US$76m |
| Jun 30 2021 | n/a | n/a | -US$67m |
| Mar 31 2021 | n/a | n/a | -US$58m |
| Dec 31 2020 | US$5m | US$549k | -US$52m |
| Sep 30 2020 | n/a | n/a | -US$48m |
| Jun 30 2020 | n/a | n/a | -US$43m |
| Mar 31 2020 | n/a | n/a | -US$38m |
| Dec 31 2019 | US$668k | US$477k | -US$32m |
| Sep 30 2019 | n/a | n/a | -US$26m |
| Jun 30 2019 | n/a | n/a | -US$21m |
| Mar 31 2019 | n/a | n/a | -US$16m |
| Dec 31 2018 | US$1m | US$464k | -US$13m |
Compensatie versus markt: Ed's total compensation ($USD3.53M) is about average for companies of similar size in the US market ($USD3.23M).
Compensatie versus inkomsten: Ed's compensation has been consistent with company performance over the past year.
CEO
Ed Kaye (75 yo)
7yrs
Tenure
US$3,533,210
Compensatie
Dr. Edward M. Kaye, also known as Ed, M.D., Ph.D. has been Special Regulatory and Scientific Advisor of Sarepta Therapeutics, Inc. since June 28, 2017. He serves as Independent Director at Avidity Bioscien...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 7yrs | US$3.53m | 0.051% $ 331.8k | |
| Co-Founder & Independent Director | no data | US$198.33k | 0.77% $ 5.0m | |
| Chief Medical Officer | 7yrs | US$1.65m | 0.0047% $ 30.5k | |
| Co-Founder & Senior VP of Discovery Research | no data | geen gegevens | geen gegevens | |
| Chief Financial Officer | less than a year | geen gegevens | geen gegevens | |
| Head of Investor Relations | no data | geen gegevens | geen gegevens | |
| Corporate Secretary & General Counsel | 3.8yrs | geen gegevens | 0.0049% $ 31.9k | |
| Chief Communications Officer | 3.8yrs | geen gegevens | geen gegevens | |
| Chief Human Resources Officer | 5yrs | geen gegevens | geen gegevens | |
| Chief Business Officer | less than a year | US$869.86k | 0% $ 0 | |
| Chief Regulatory Officer | 5.8yrs | geen gegevens | geen gegevens | |
| Chief Commercial Officer | less than a year | geen gegevens | geen gegevens |
3.8yrs
Gemiddelde duur
54.5yo
Gemiddelde leeftijd
Ervaren management: STOK's management team is considered experienced (3.8 years average tenure).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 7yrs | US$3.53m | 0.051% $ 331.8k | |
| Co-Founder & Independent Director | 10.3yrs | US$198.33k | 0.77% $ 5.0m | |
| Independent Chairman of the Board | 9.3yrs | US$237.33k | 3.56% $ 23.0m | |
| Independent Director | 9.1yrs | US$198.33k | 0.034% $ 221.0k | |
| Independent Director | 1.1yrs | US$394.03k | 0% $ 0 | |
| Independent Director | 4.2yrs | US$199.33k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$206.83k | 0% $ 0 | |
| Independent Director | 5.3yrs | US$209.33k | 0% $ 0 | |
| Independent Director | 6.1yrs | US$211.83k | 0.060% $ 390.1k |
6.1yrs
Gemiddelde duur
61yo
Gemiddelde leeftijd
Ervaren bestuur: STOK's board of directors are considered experienced (6.1 years average tenure).